Podcasts about pdms

Say goodbye to messy curly cords and more potential failure points.Steering wheel-mounted controls make it easier to adjust key functions on the fly, but getting those signals from the wheel to the car is not as simple as it sounds. Running multiple wires through a rotating steering column is unreliable, time-consuming, and they can be prone to failure due to the nature of their use. Zestek has developed a CAN-based steering wheel PCB solution (CAN hub) that simplifies installation, reduces wiring complexity, and integrates seamlessly with MoTeC ECUs, dashes, and PDMs.Use ‘PODCAST75' for $75 off your first HPA course here: https://hpcdmy.co/hpa-tuned-inWith only four wires required for full functionality (CAN high, CAN low, power, and ground), this system eliminates the need for bulky wiring looms. The pogo pin system built into the quick-release hub provides a clean and hassle-free connection, removing the need for traditional curly cords. A pre-configured DBC file is available for MoTeC users (and we're sure more in the future), while others can configure the CAN signals using a spreadsheet for quick setup.Each button and switch is fully customizable, including momentary and latching functions, as well as full-spectrum RGB LED feedback. Paddles can be used for more than just shifting, allowing functions like anti-lag, launch control, and nitrous activation. It is also sim racing compatible, making it easy to use the same wheel for both real and virtual driving while you wait out the winter weather.

After 1.5 years into this process I'm going to give an update on my multiple PDMs (poly-domestic marriages) in several different countries, including what's going on and what I've learned and changed.

In this podcast episode, MRS Bulletin's Sophia Chen interviews Gwangmin Bae of Korea University about his work with colleagues on the design of a new smart window system that utilizes compression. Like other smart windows, this window makes use of pores within the material to adjust its transparency. However, instead of using a stretchy material that controls light scattering through the pores, Bae and colleagues used a material that compresses in thickness. That is, the window becomes more transparent when it is compressed. The researchers place this structured porous material made of the polymer polydimethylsiloxane or PDMS between two panes of glass to create the smart window. This work was published in a recent issue of Nature Communications.

Send us a Text Message.$100 off your HP Academy course purchase! Use Code: BLIND100Its a big decision to pick and dash and/or pdm... and I sit down with Andre Simon to discuss what to take into account and some best practices to set them up! Both can be just seen as IG bling OR super powerful tools to help improve your racing and your race car! Support any of your favorite podcasts by... sharing, downloading, reviewing, and giving it at 5 star rating. 

What does it take to build, tune, and drive a monster Mitsubishi Evolution VIII with a 4.1-litre VR38DETT putting down 1065 hp to all four treads — on pump gas, no less? On this episode of Tuned In, we talk to the Armchair Tuner to find out.Use “EVO100” to get $100 off HPA's Tuning Starter Package: https://hpcdmy.co/tuningpackagebConrad Bradley has been building fast cars and bikes for a long time, although he currently works outside of the automotive industry in the nuclear field. Conrad couldn't tell us much about his current work projects for obvious reasons, but when it comes to his many interesting automotive projects, he's an open book.Over the years, Conrad's built many fast cars — from rapid Subarus, to even faster Evos, to an immaculate Beams-powered AE86 — we discuss all those builds in this conversation, but it's his one-of-a-kind Evolution VIII that we're most interested in.We dive deep into this build with Conrad, digging into the big questions, like:Why ditch the 4G63?Why the VR38DETT?How is it still 4WD?What was the hardest part of the build and how was it dealt with? Has it changed how the car drives?Why even build something as unique as this car in the first place?This is a fascinating look into a very serious build that presented a lot of problems, requiring unique solutions.Further into the conversation, we also discuss the challenges of owning and operating a tuning shop, reflashing challenges, Evo strengths and weaknesses, and much more. This is a great listen for anyone interested in thinking outside the box when it comes to building cars and going fast. Follow Conrad here:IG: @armchairtunerFB: Armchairtuner YT: Armchair TunerDon't forget, you can use “EVO100” to get $100 off HPA's Tuning Starter Package: https://hpcdmy.co/tuningpackagebTime Stamps:4:25 How did you form an interest in cars?14:01 How did you end up owning a tuning shop?20:43 Pros and cons of owning a tuning shop.27:50 Transition from motorbikes to cars.29:23 Why JDM vehicles?34:05 Reflashing JDM vehicles.39:29 Was it Subaru's reliability issues that drove you to the Mitsubishi platform?43:04 Toyota AE86.58:03 Back into the Mitsubishi world? Evo X.1:04:17 Manufacturers making it difficult for us to tune modern engines.1:09:34 What came after the Evo X?1:11:31 Building an Evo for drag racing.1:24:36 How did the Evo GT-R come about?1:27:36 What was involved in fitting the VR38?1:34:49 What is the transmission?1:41:22 Motec M1 custom package for 4wd setup1:47:10 How much does it weigh with the VR38?1:48:06 What was the goal for the VR38?1:56:07 Are you running PDMs?1:58:50 Are you using the data from all your sensors for anything in particular?2:00:02 Is the Evo GT-R finished?2:06:09 Final 3 questions.

My client recommended I reach out to Ronan due to the valuable work he is doing in building connection. Ronan is a facilitator whos work with groups involves a variety of methodologies like positive psychology, sports psychology, CBT, Compassionate Inquiry, PDMS, and the Hero's Journey.  Working with prison inmates, high performance athletes, top tier corporate groups and more, his ability to create a safe and energetic space to explore connection, growth and express vulnerability is simply phenomenal. Ronan discusses our universal expression of human needs, the power of connection, the common threads that connect elite athletes and convicted criminals and so much more in this fantastic conversation. Learn more about Ronan here       Connect with me on IG: @conorosheafit To learn more about my online coaching program for men over 30: Click here

Ronan Conway is a facilitator whos work with groups involves a variety of methodologies like positive psychology, sports psychology, CBT, Compassionate Inquiry, PDMS, and the Hero's Journey. Working with prison inmates, high performance athletes, top tier corporate groups and more, his ability to create a safe and energetic space to explore connection, growth and express vulnerability is simply phenomenal. Ronan discusses our universal expression of human needs, the power of connection, the common threads that connect elite athletes and convicted criminals and so much more in this fantastic conversation. Prymal: ⁠@prymalpro⁠ Dan: ⁠@thedancampion⁠ Ronan: @conway.ronan Get your FREE copy of 20 Books and Podcasts to Change Your Life: ⁠https://mailchi.mp/prymal/bookspodcasts

Global Product Management Talk is pleased to bring you the next episode of... Product Mastery Now with host Chad McAllister, PhD. The podcast is all about helping people involved in innovation and managing products become more successful, grow their careers, and STANDOUT from their peers. About the Episode:  Today we are talking about the skills product managers need to grow their careers. To help us, Neha Bansal  is with us. She is the Head of Merchant Growth and Monetization for Google's B2B ecommerce business, where she is leading efforts to build the next $1B+ B2B business for the company. Before joining Google, Neha worked as a Management Consultant at Essex Product Consulting, where she helped organizations build products. Outside of her day job, she has guided many PdMs in reaching their career goals, and consequently, has good insights about the skills they need.

Innovation technologique Liliane Bettencourt (2022-2023) - Lydéric BocquetCollège de FranceAnnée 2022-2023Colloque - La nanofluidique à la croisée des chemins : New Approaches in Nanofluidics: Carbon Nanotubes Mechanical ResonatorsI will present our work in the direction of combining mechanical resonator and nanofluidic channel with a carbon nanotube.First, I will discuss how mechanical resonators will allow to answer, experimentally, open questions in the nanofluidic community about the structure of water, the phase diagram and the mechanism behind the fast flow observed in carbon nanotube. Second, I will show that SU8 microfluidic allows to combine antagonist worlds of fluidics (ambient pressure) and mechanics (secondary vacuum). Such devices can sustain large water pressure up to 5 bars and do not degrade over time. Porosity of SU8 is equal or better to PDMS, the standard in fluidics. Moving to carbon nanotube nanomechanical resonators, I will show that they exhibit exquisite mass sensitivity down to 70 yg, even at room temperature. This feature is observed in several devices, making it a reliable asset. I will discuss the limitations to the sensitivity in terms of thermomechanical noise, frequency fluctuations, etc.Finally, I will demonstrate that electrons in carbon nanotubes can distinguish water adsorbed on the surface of the nanotube from water confined inside the nanotube.Again, this feature is reproducible in several devices and independent of the metallicity of the nanotube.Adrien NouryAdrien Noury received his PhD in Physics (Photonics and Material Sciences) in 2014 from Univ. Paris Sud, on carbon nanotubes hybrid photonics. He then joined the group of Adrian Bachtold in ICFO Barcelona to work on quantum electromechanics with graphene drums, and later Helium superfluids on nanotube mechanical resonator. Since 2017 he is CNRS researcher in L2C, Montpellier, where he started and led the Nanomechanics group. His research focuses on harnessing the exceptional sensitivity of nanotube mechanical resonators in order to adress challenging questions in Physics.

Diese Folge ist eine tiefe Verbeugung vor der Leistung der Krankenhaus-IT. Geplant war die Folge von Christian und Renato als ein kurzer Überblick über die verschiedenen Systeme, die im Krankenhaus neben KIS, PDMS, RIS und PACS verwaltet werden müssen. Als wir dann aber feststellen mussten, WIE VIELE verschiedene (teilweise sehr komplexe) IT-Systeme in einem Krankenhaus existieren, ist uns selbst ein wenig die Kinnlade heruntergefallen. Und der Überblick, den wir in dieser Folge geben ist noch nicht mal ansatzweise vollständig. Natürlich kann man bei einer solchen Menge thematisch nicht allzu sehr in die Tiefe gehen. Aber zu vielen der Systeme gibt es bereits Podcast-Folgen, sodass man Details auch dort anhören kann. Am Ende sollte auf jeden Fall der Eindruck zurück bleiben: So eine Krankenhaus-Systemlandschaft ist ganz schön vielfältig und aufregend!

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.04.14.536862v1?rss=1 Authors: Carnicer-Lombarte, A., Boys, A., Guemes, A., Gurke, J., Velasco-Bosom, S., Hilton, S., Barone, D. G., Malliaras, G. G. Abstract: Implantable devices interfacing with peripheral nerves exhibit limited longevity and resolution. Poor nerve-electrode interface quality, invasive surgical placement and development of foreign body reaction combine to limit research and clinical application of these devices. Here, we develop cuff implants with an ultraconformable design that achieve high-quality and stable interfacing with nerves in chronic implantation scenarios. When implanted in sensorimotor nerves of the arm in awake rats for 21 days, the devices recorded nerve action potentials with fascicle-specific resolution and extracted from these the conduction velocity and direction of propagation. The ultraconformable cuffs exhibited high biocompatibility, producing lower levels of fibrotic scarring than clinically equivalent PDMS silicone cuffs. In addition to recording nerve activity, the devices were able to modulate nerve activity at sub-nerve resolution to produce a wide range of paw movements. The developed implantable devices represent a platform enabling new forms of fine nerve signal sensing and modulation, with applications in physiology research and closed-loop therapeutics. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

A cidade da Serra passa a contar com um um novo Plano Diretor Municipal. É o chamado "Plano Diretor Municipal Sustentável" (PDMS) cuja expectativa é trazer ordenamento às questões ambientais e sustentáveis da cidade. A sua revisão passa a ser realizada em cinco anos e não em 10, como anteriormente, "evitando que fique obsoleto diante de tantas mudanças que ocorrem no cenário de um grande município como a Serra", segundo a administração municipal. O plano aponta áreas melhor infra-estruturadas com rede esgoto, escolas, creches e asfalto, priorizando um melhor adensamento, que é o maior número de pessoas por metro quadrado.

This is the third series of Agile Framework Fight night. This fight night was hosted in Seattle by Beyond Agile. Like the first Agile Framework Fight Night, we brought together another winning panel of experts to represent the frameworks of DA, Fast Agile, LeSS, and SaFE. Agile Framework Fight Night, the SECOND SERIES happened at Beyond Agile, transmitted from Seattle. You can find Beyond Agile at Meetup.com here: https://www.meetup.com/BeyondAgile/ The expert panelists are: Ricardo “Dad of Doom” Garcia from Team DA This “Dad of Doom” has over 30 years of industry experience and has implemented and managed numerous software projects using Agile Practices for Fortune 500 companies. His work has been featured in white papers, cover stories in magazines, and is a frequent speaker at conferences and Agile expert panels. He is the organizer behind Seattle Disciplined Agile Meetup: https://www.meetup.com/Seattle-Disciplined-Agile-Meetup/ Ron Quartel AKA "Crocodile Ron-dee" Software Crafter, Disruptor, Pioneer and Intrapreneuer. On a mission to unleash the human spirit in the workplace. Founder of FAST Agile. https://www.fastagile.io Viktor "the Simplifier" Grgic Viktor is an Agile Coach, software developer and Certified LeSS trainer with 17 years of experience in delivering enterprise systems and Agile adoptions. He worked first 15 years in The Netherlands, and since 2013 in Hong Kong. https://less.works/profiles/viktor-grgic Barry Smith, the Nexus Knight Is a member of Unify's Lean-Agile practice, and committed to helping product teams to enjoy a better way of working and delivering exceptional value to their customers. His over 25+ years of working in technology has shown him that innovation can be fostered anywhere, from startups to Fortune 500 firms. Lancer “Unkind” Kind, moderating “Unkind” lives in Kirkland, and loves nothing more than writing micro tested software. For the last five years he has delivered consulting services in China, India, as well as the USA. He's a publishing author of science fiction and Agile Noir, a project management business novel. He's podcasting at Agile Thoughts, 敏捷理念 (the Chinese edition of Agile Thoughts), and SciFi Thoughts. His Agile at scale business novel is “continuously delivered” via Lean Pub at: https://leanpub.com/AgileGrande Here is a link to this Beyond Agile event in Meetup which contains comments about the fight night: https://www.meetup.com/beyondagile/events/286465281/ You can listen to the first and second Bouts of Agile Framework Fight Night series here: https://agilenoir.biz/en/agilethoughts/agile-framework-fight-night/ Chat record from Bout 3 of Agile Framework Fight Night Jon Jorgensen to Everyone (10:04 PM) I know Niels Pflaeging. Would you like me to ask him if he'd like to speak to this group? Aki Namioka to Everyone (10:05 PM) Where is Niels Pflaeging located? Jon Jorgensen to Everyone (10:06 PM) Germany Ricardo to Everyone (10:08 PM) For Jobs at Costco pls send me an email at ricardo.garcia@costco.com shama to Everyone (10:08 PM) Ron Lichty to Everyone (10:10 PM) Enterprise Agile Global Community: Dennis Stevens: Agile for Execs: https://us02web.zoom.us/j/89071064881?pwd=a1NoY2ptN3BudGd1OGNINXNtQ0ZYQT09 Josh Novajosky to Everyone (10:11 PM) Amazing shirt Ron Barry L Smith to Everyone (10:18 PM) “LeSS”, of course, refers to “Lightweight Similarity to Scrum" - really, they copied all their good ideas from Nexus. Ron Lichty to Everyone (10:24 PM) I thought I heard Paige Watson describe the FAST meeting as five PdMs bringing in the five priorities for the cycle? Is a “nexus” essentially what others are calling a "tribe”? Barry L Smith to Everyone (10:27 PM) Yes, similar to tribe or ART (Agile Release Train) - the group of teams that are collaborating in developing & delivering a Product Backlog. Jon Jorgensen to Everyone (10:29 PM) Seems like HUGE enterprises would have HUGE concerns (problems) to resolve for the people of the world and inside the organization. Silpa to Everyone (10:31 PM) Our scrum team is of 16 members. We formed mini scrum teams of 4 in each team with 1 PO, 1 SM, making sure we have a process expert supporting each mini scrum team. Jon Jorgensen to Everyone (10:31 PM) The crafting of experiments to see if hardware/software or other kinds of “works” is what runs through an organization. Which of the Frameworks are predicated on the assumption that software products are the resolution of these concerns? Barry L Smith to Everyone (10:32 PM) Jon, are you essentially asking, “Is experimentation a core element of your framework”? Jon Jorgensen to Everyone (10:32 PM) yes Me to Aki Namioka (Direct Message) (10:33 PM) What is our "finish" time? One hour or? Jon Jorgensen to Everyone (10:33 PM) And “What kind of professionals are involved in the experiment?” Barry L Smith to Everyone (10:34 PM)

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.07.515431v1?rss=1 Authors: Girardin, S., Ihle, S. J., Menghini, A., Krubner, M., Tognola, L., Duru, J., Ruff, T., Fruh, I., Muller, M., Vörös, J. Abstract: Novel in vitro platforms based on human neurons are needed to improve early drug testing and address the stalling drug discovery in neurological disorders. Topologically controlled circuits of human induced pluripotent stem cell (iPSC)-derived neurons have the potential to become such a testing system. In this work, we build in vitro co-cultured circuits of human iPSC-derived neurons and rat primary glial cells using microfabricated polydimethylsiloxane (PDMS) structures on microelectrode arrays (MEAs). Such circuits are created by seeding either dissociated cells or pre-aggregated spheroids at different neuron-to-glia ratios. Furthermore, an antifouling coating is developed to prevent axonal overgrowth in undesired locations of the microstructure. We assess the electrophysiological properties of different types of circuits over more than 50 days, including their stimulation-induced neural activity. Finally, we demonstrate the effect of magnesium chloride on the electrical activity of our iPSC circuits as a proof-of-concept for screening of neuroactive compounds. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

It's It's “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: a troubling new study about how many people with diabetes ration insulin, a new study looks at OpenAPS compared to traditional pumps, more research on Beta Bionics' iLet pump, an old diabetes drug might help in the fight against dementia, and more! Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX A new study shows nearly 1 in 5 adults in the U.S. with diabetes either skipped, delayed or used less insulin than was needed to save money. That comes out to roughly 1.3 million adults, or 16.5% of those who need insulin. The findings were based on data from the 2021 National Health Interview Survey, which is conducted annually by the Centers for Disease Control and Prevention and which interviews tens of thousands of Americans about their health-related experiences. It was the first time that the CDC had included questions about insulin use, though concerns about sky-high insulin prices have been reported for years. Starting Jan. 1, the Inflation Reduction Act, signed into law by President Joe Biden in August, will cap the monthly cost of insulin at $35 for seniors on Medicare. The bill, however, will leave out millions of Americans with private health insurance as well as those who are uninsured. It was also found to be more common among people with type 1 diabetes, at 18.6%, compared to those with type 2 diabetes, at 15.8% https://www.nbcnews.com/health/health-news/insulin-prices-many-adults-diabetes-ration-insulin-study-finds-rcna52287?cid=sm_npd_nn_tw_ma XX New islet cell transplant study looks very promising. Long term outcomes of two phase 3 clinical trials shows many patients didn't need insulin to maintain their blood sugar for up to eight years. It also showed that a new approach required fewer transplants than typical and was exceedingly safe. These trials included people who had kidney transplants and showed islet cell transplants for those people was safe and effective. 75 percent who initially were able to come off insulin therapy, more than half maintained total insulin independence, meaning they needed no additional insulin injections throughout the years of follow-up. https://www.pennmedicine.org/news/news-releases/2022/october/new-islet-transplant-method-leads-to-insulin-independence XX Study out of New Zealand looked at DIY diabetes tech and compared to some commercial offerings. Not sure what they were tyring to prvoe here because they looked at a closed loop system OpenAPS and compared it to a regular old pump and CGM system with no automation. No surprisingly, the people with type 1 in the AID group had much more time in range – about 14 percent more – than those using a standalone pump and CGM. No severe lows or DKA in either group. But these days, IMO, looking at an automated insulin delivery system to a pump and CGM that don't communicate is like comparing apples and chain saws. https://www.medtechdive.com/news/do-it-yourself-artificial-pancreas-diabetes/633888/ XX More good news for the iLet Bionic Pancreas. A clinical trial, conducted at 16 clinical sites across the United States, enrolled 326 participants ages 6 to 79 years who had type 1 diabetes and had been using insulin for at least 1 year. Participants were randomly allocated to a treatment group using the bionic pancreas or a standard-of-care control group that continued with their pre-trial method of glucose monitoring and insulin dosing. In participants using the bionic pancreas, A1C improved from 7.9% to 7.3%, yet remained unchanged among the control group. The iLet doesn't use carb counting – just meal announcements and it sets basal rates with just the user's body weight. It's currently in front of the US FDA, awaiting approval. XX Insulet issued an urgent medical device correction on Monday related to battery problems with a component of its Omnipod DASH system. The device uses a wearable insulin pod that's controlled by a personal diabetes manager (PDM), a smartphone-like device that does the calculations for bolus insulin doses. Insulet plans to replace the PDMs for all of its current Omnipod DASH users globally, incurring an aggregate charge of $35 million to $45 million, J.P. Morgan Analyst Robbie Marcus wrote in a Monday research note. Insulet said it received reports of some Omnipod DASH users having battery problems with their PDM devices, including the battery swelling, fluid leaking from the battery, and in rare cases, extreme overheating. In a letter to users, the company said it plans to ship updated devices to all current Omnipod DASH customers in the coming months. The battery issue applies to all of Insulet's Omnipod DASH PDMs, but the likelihood of problems may increase if the device has been in use longer than 18 months. Charging the device to a full battery and leaving it on the charger overnight also increases the risk. So far, Insulet said it has not received reports of any injuries related to the battery issues. The company advised patients to monitor their PDMs for battery problems, including a bulging back cover and the device losing its charge very quickly, overheating or emitting an odor. If patients notice any of these problems, they should not charge the device, stop using the system and switch to a backup insulin plan as soon as they can. Users can also contact Insulet for a temporary replacement device. https://www.medtechdive.com/news/insulet-battery-problems-omnipod-dash/634275/ XX MDT) announced today that it introduced a new diabetes management program for users of the MiniMed 770G insulin pump. The medtech giant calls the new program My Insights. It designed it exclusively for individuals using the MiniMed 770G hybrid closed-loop insulin delivery system. Using an individual's data, My Insight provides personalized tips, trends and reminders to help customers manage their diabetes. Its personalized recommendations come through via monthly emails with educational content. Medtronic aims to make the content relevant based on what the individual experiences. Medtronic said it represents the first diabetes management program to go beyond “generalized tips.” Instead, it offers personalized suggestions using data from the integrated insulin pump system. The company said it made My Insights available in the U.S. to anyone using MiniMed 770G. https://www.drugdeliverybusiness.com/medtronic-launches-diabetes-insights-program-for-minimed-users/ XX Some countries are seeing shortages of Ozempic, a weekly injectable meant for people with diabetes but can be prescribe off label for weight loss. Demand has gone way up since some Tik Tok and social media influencers have shared Ozempic as a weight loss drug. Diabetes groups and especially Australian advocacy groups have advised doctors to limit prescribing the drug to people with Type 2 diabetes. https://www.abc.net.au/news/2022-10-17/ozempic-weight-loss-demand-type-2-diabetes-drug-shortage/101542226 XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX XX XX New research shows an older drug for type 2 might help reduce the risk for dementia. People with diabetes are at higher risk of developing dementia. These researchers looked though 500-hundred thousand past medical records and found that an older class of type 2 diabetes medication known as glitazones helps reduce a person's dementia risk by 22%. These reerahres say its very promising but they want to see more real world study and also combine glitazones with other types of treatments https://www.medicalnewstoday.com/articles/type-2-diabetes-drug-may-help-lower-dementia-risk-by-22 XX On the podcast next week.. Kerri Sparling from SixUntilMe The past episode was all about teens and type 1 – a deep dive into why teen retreats work from the people who organize a great one.. and how adults with type 1 still use the lessons they learned as teens. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Why should you be concentric-twisting your wiring? What tools should you buy if you're looking to build a harness? And when is it actually OK to use a soldering iron? This week on Tuned In, Matt Sanderson from Level Motorsport Wiring aims to answer these questions and many more. Use ‘PODCAST75' for $75 off your first HPA course here: https://hpcdmy.co/hpa-tuned-inMatt is a seasoned expert when it comes to professional-level motorsport wiring — his work is so good, we've been using his Instagram as inspiration for our own projects for a good while now. Based in the UK, Matt has a background in general mechanical work, which eventually transitioned into auto-electrical before the decision was made to start a company — Level Motorsport Wiring — that specialised in the high-end side of the wiring game.In this conversation, Matt and Tuned In host Andre Simon explore the ins and outs of designing and building a high-end motorsport harness, following the process from start to finish. There's a lot that goes into the planning and documenting side of the job that may not be immediately obvious. That, combined with some great wiring tips and tricks, make this an unmissable episode for anyone that has an interest in wiring, PDMs, "milspec", and motorsport electronics in general. Follow Matt here:IG: @levelmsw_FB: Level Motorsport WiringTK: @LevelMSWYT: Level Motorsport WiringWWW: levelmotorsportelectronics.co.ukWant to learn more about motorsport wiring? Claim your spot for the next FREE lesson: https://hpcdmy.co/wireb

This week, please join author Guest Host Mercedes Carnethon, Author Brian Bergmark, and Associate Editor Parag Joshi as they discuss the article “Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.” Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-host. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center in Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Well Carolyn, this week's feature, non-high density lipoprotein cholesterol levels in statin treated patients with elevated cholesterol. We're going to hear from the TRANSLATE-TIMI 70 study. But before we get to that, how about we grab a cup of coffee and discuss some of the other articles in the issue? Would you like to go first? Dr. Carolyn Lam: I would. And by the way, that feature is going to be all exciting. It was discussed at the American College of Cardiology. But okay, how about from cholesterol to vitamins? Let's start with the Greg quiz. Greg, which vitamins have been associated with arterial calcification? Is it A, B, C, D, E? Dr. Greg Hundley: I'm going to pick E and K. Dr. Carolyn Lam: You're smart. Indeed. Vitamin K2, also known as menaquinone-7 is the most effective co-factor for the carboxylation of proteins involved in the inhibition of arterial calcification. Furthermore, combined low vitamin K and low vitamin D have been associated with increased all-cause mortality risk. And so, today's paper is from Dr. Diederichsen from Odense University Hospital in Denmark and colleagues really present the first double-blind, randomized controlled trial to test whether vitamin K2, a drug-targeting processes of calcification in addition to vitamin D, could slow the progression of aortic valve calcification and stenosis. So, in a randomized double-blind multicenter trial, men from the community with an aortic valve calcium score above 300 arbitrary units on cardiac non-contrast CT were randomized to daily treatment with 720 micrograms of vitamin K2 plus 25 micrograms of vitamin D or matching placebo for 24 months. And the primary outcome was the change in aortic valve calcium score. Dr. Greg Hundley: Carolyn, so menaquinone-7 and aortic valve score. So, what were the results? Dr. Carolyn Lam: Menaquinone-7 had no major effect on the progression of aortic valve calcification as assessed by CT or echo. High-dose menaquinone-7 was, however, safe and well tolerated. Now, some limitations is that this external validity is limited to men aged 65 to 74 with aortic valve calcification scores of greater or equals to 300 arbitrary units. Thus, caution is needed if we extrapolate these findings and other pathways need to be explored in order to identify an effective therapy for this unmet clinical need. Dr. Greg Hundley: Wow, very nice Carolyn. Well, my first article comes to us from Dr. Michael Laflamme from the University Health Network. And Carolyn, human pluripotent stem cell-derived cardiomyocytes or hPSC-CMs exhibit promise for application in cardiac regeneration, but their translational potential is limited by an immature phenotype. So Carolyn, this research team hypothesized that large scale manufacturing of mature hPSC-CMs could be achieved via culture on polydimethylsiloxane, and we're going to call that PDMS, lined roller bottles and that the transplantation of these cells would mediate better structural and functional outcomes then with conventional immature hPSC-CMs populations. Dr. Carolyn Lam: Oh, that's neat, Greg. So, what did they find? Dr. Greg Hundley: Right, Carolyn. So, these authors demonstrated the economic generation of greater than one times 10 to the eighth mature hPSC-CMs per PDMS line roller bottle. And compared to their counterparts, PDMS matured hPSC-CMs exhibited increased cardiac gene expression and more mature structural and functional properties in vitro. More importantly, intracardiac graphs formed with PDMS matured myocytes showed greatly enhanced structured alignment, better host graft electromechanical integration, less pro arrhythmic behavior, and greater beneficial effects on contractile function. So in summary, Carolyn, this team describes practical methods for the scale generation of mature human pluripotent stem cell-derived cardiomyocytes and provide the first evidence that the transplantation of more mature cardiomyocytes yields better outcomes in vivo. And there's a wonderful editorial by Professor Murray entitled Flexing Their Muscles: Maturation of Stems Cell-Derived Cardiomyocytes on Elastomeric Substrates to Enhance Cardiac Repair. Dr. Carolyn Lam: Wow! That's really significant. Thank you, Greg. Well, the next paper is the largest genome-wide association meta-analysis of plasma ACE2 levels in over 28,000 individuals. And this is from Dr. Xia Chen from Fudan University and Dr. James Wilson from University of Edinburgh in UK, and their colleagues. And guess what, it focuses on severe acute respiratory syndrome coronavirus 2, the etiologic agent of COVID 19. And we know that that enters human cells using the ACE2 protein as a receptor. ACE2 is thus key to the infection and treatment of the coronavirus. ACE2 is highly expressed in the heart, respiratory and gastrointestinal tracts, playing important regulatory roles in the cardiovascular and other biologic systems. Dr. Greg Hundley: Wow, Carolyn. ACE2, and also a very important topic here with SARS-COVID-2. So, what did they find? Dr. Carolyn Lam: First, the overall heritability of ACE2 level is 16% of which 30% can be explained by 10 protein quantitative trait loci identified in this study. ACE2 level is genetically correlated with both COVID-19 and cardiovascular. Elevated ACE2 levels show a causal relationship with COVID-19 severity, hospitalization and infection as shown by Mendelian randomization analyses. ACE2 regulatory variants are enriched on DNA methylation sites in immune cells. Dr. Greg Hundley: Wow, Carolyn. So, elevated ACE2 and a causal relationship with COVID-19 severity. So tell us, what are the clinical applications of this really nice study? Dr. Carolyn Lam: The causal evidence of ACE2 suggests that pharmacological inhibition of circulating ACE2 may be a promising approach for treating COVID-19 or its comorbidities. Transcription factors that play essential roles in ACE2 generation could provide alternative paths to pharmacological modulation of ACE2 plasma levels. The genetic correlations between ACE2 and both COVID-19 and cardiovascular disease imply that the cardiovascular complications seen in COVID-19 patients may be intrinsic to the disease and mechanically or/and mechanistically-driven by ACE2. Isn't that neat? Dr. Greg Hundley: You bet, Carolyn. Boy, what an exciting issue. And we've got other articles in this issue. Dr. Carolyn Lam: Yeah. Now, let me start this time. There's an exchange of letters between Drs. Duan and Chang regarding the article “Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.” There's a Perspective piece by Dr. Morris, “The Updated Heart Failure Guidelines: Time for a Refresh.” Love that piece! There's an AHA Update piece (AHA President's Page) by Dr. Elkin on The Road to Equity in Brain Health, and ECG challenge by Dr. Kolominsky, Electrical Extremists in a Critically ill Patient, and an On My Mind Paper by Dr. Paulus entitled “Border Disputes Between Heart Failure Phenotypes.” Dr. Greg Hundley: Wow, Carolyn. And I've got two Research Letters. The first from Professor Groeneveld entitled “Prevalence of Short-Coupled Ventricular Fibrillation in a Large Cohort of Dutch Idiopathic Ventricular Fibrillation Patients.” And then a second Research Letter from Professor Yamashita entitled “Single Cell RNA Sequence Reveals a Distinct Immune Landscape of Myeloid Cells in Coronary Culprit Plaques Causing Acute Coronary Syndrome.” Well Carolyn, now, we get to go onto our feature, vupanorsen on non-high-density lipoprotein cholesterol levels and catching up with TIMI 70. Dr. Carolyn Lam: Let's go. Dr. Mercedes Carnethon: So, good morning listeners. I'm really pleased to invite you to this episode of our Circulation on the Run podcast. For those of you who don't hear me often, I'm stepping in as a guest host today. My name is Mercedes Carnahan from the Northwestern University Feinberg School of Medicine. And I'm really excited to be joined today by Dr. Brian Bergmark, and associate editor, Dr. Parag Joshi. And we will have today Dr. Bergmark discussing his new article published with us on the effects of vupanorsen on non-HDL cholesterol levels in the TRANSLATE-TIMI 70 trial. We're really thrilled to have you with us here today, Brian, to talk about the really important findings coming from this trial. So to start us off, just tell us, what did you find? Dr. Brian Bergmark: Great. Thank you so much. It's really a pleasure to be here and I'm grateful for the opportunity. So, in the big picture, despite numerous agents to reduce lipid-mediated cardiovascular risk, obviously, residual risk remains and there are novel targets to address that risk. One of them is angiopoietin-like 3, which is a protein made in the liver. Angiopoietin-like 3 or ANGPTL3 inhibits lipoprotein lipases among other lipases, and thereby interferes with metabolism of triglyceride-rich lipoproteins. And so, the idea here was that if ANGPTL3 could be inhibited that LPL or lipoprotein lipase function could be augmented and metabolism of these lipoproteins could be augmented. And so, what we did is we took patients with an elevated non-HDL cholesterol, at least 100 milligrams per deciliter, and elevated triglycerides, 150 to 500 milligrams per deciliter, and randomized them to placebo or one of seven doses of vupanorsen, which is an antisense oligonucleotide, which inhibits the synthesis of ANGPTL3 in the liver. We then follow them to see what the impact was on their non-HDL cholesterol, as well as other lipid parameters through 24 weeks. Dr. Mercedes Carnethon: Thank you so much. It's a wonderful design, and I'm really excited to hear a little bit more about what you found. Dr. Brian Bergmark: Great. So, the primary endpoint was the change in non-HDL cholesterol from baseline to 24 weeks. And we did find that all vupanorsen regimens reduced non-HDL cholesterol in a statistically significant manner. The magnitude of that effect was up to 27.7% in one of the dose arms or about 28%. We also saw a statistically significant reductions in the target ANGPTL3 up to about a 95% reduction in the highest dose arm, as well as statistically significant reductions in triglycerides at all of the dose regimens. The effect on LDL cholesterol and on apolipoprotein B or apo B was variable across regimens and only statistically significant in a few of the dose arms. We also found several safety signals. One, there appeared to be higher rates of injection site reactions in the skin at higher total monthly doses. We also found higher rates of elevation in liver enzymes, AST and ALT at higher total monthly doses. And we also found significant increases in hepatic fat fraction or the fat content of the liver at higher total monthly doses. Dr. Brian Bergmark: In the end, we found that while statistically significant, the magnitude of the reduction in non-HDL cholesterol was modest as was the reduction in apo B. And so, the goal here was to find a dose that might have a reduction of a magnitude that would be clinically meaningful for cardiovascular risk reduction. We were underwhelmed by the magnitude of that reduction, and then it was paired with these safety signals, which if there's interest, we could get into more detail in our thinking about why those occurred, what the implications are, but suffice it to say that there were medically meaningful safety concerns paired with a modest reduction in non-HDL cholesterol. Dr. Mercedes Carnethon: Thank you for that excellent summary. Before I turn it over to the associate editor, I read this with great interest, and in particular, looking at one of the first figures in the paper, which is demonstrating the adjusted change at 24 weeks across different doses and based on how frequently the doses were given the four week as compared with the two week. And one thing that really stood out to me was the clear dose response with the four week regimens with the higher doses appearing to demonstrate the greatest reductions but a less clear signal with the two week regimens. Do you have any hypotheses about why these patterns appeared so different? Dr. Brian Bergmark: Yeah. It's a great question. So, the responsiveness of this is something of interest here I think. So, if you look at the effect of the drug on its target, ANGPTL3, there is a very clear dose response, so there's no doubt that higher doses were impacting the target ANGPTL3 to a greater extent. So, one of the most direct effects would be on triglycerides, one of the most direct lipid effects, and that appears pretty close to a dose response relationship within each of these frequencies of administration. But once you start getting to non-HDL cholesterol, it starts to break down a bit. And is it simply because of random chance or is there actually something distinct going on with how the lipids are being metabolized? Dr. Brian Bergmark: That is something we are diving into. So, the hope would be that we actually reduce apo B, the number of these actually circulating lipoproteins as has been demonstrated with the monoclonal antibody. It's possible that with this other different mechanism in the antibody, this antisense oligonucleotide, perhaps, we're simply shifting the content of these lipoprotein molecules and decreasing the triglyceride content but not actually meaningfully modifying the amount of apo B, LDL cholesterol. And that might be part of what we're seeing with the more muted relationship between dose and the effect on non-HDL cholesterol. I don't know for certain we are diving into this a bit more with other lipid fractions, et cetera. Dr. Mercedes Carnethon: Oh, well, thank you so much for that explanation. I know that a number of people, this was extremely well received when shared at the recent American College of Cardiology meetings, and so I was really thrilled to find that this was appearing in the journal circulation. So Parag, I'm really interested in hearing your perspectives on why we knew that this was certainly a priority paper for us. Dr. Parag Joshi: Yeah. Let me first start, Brian, congratulations. Fantastic work. And we were excited to receive the paper. I think really hard to pull off trials right now or in the last couple years, so kudos to you. And I echo the sentiments from Mercedes. This is great work. Really important space, the residual risk space I think is very important of course and is critical to moving forward with improving cardiovascular health. So, one of the big picture questions and as we get to this triglyceride-rich lipoprotein lowering space, certainly, there's strong associations with residual risk, but can we impact that risk? And here, we're starting to explore that. And I think when you think of the lipoprotein space, many of us are interested in what is the effect on these lipoproteins as opposed to the cholesterol content or the triglyceride content. And non-HDL cholesterol or apo B, clearly, the better, stronger markers for that risk, so we were really excited to see this paper.   Dr. Parag Joshi: And as Brian mentioned, unfortunately, not the strongest impact here on those measures. And I want to dive into that a little more because I think that carries significant implications for the space, and I'd love to hear your thoughts on that. But overall, really fantastic work. I think my first question really is around the apo B aspect of this and the less than anticipated lowering of those levels. You hinted at this in terms of, is this shuffling cholesterol and triglycerides across particles, or do you think this could be the mechanism by which this happens through ANGPTL3? You do inhibit the levels quite a bit. Did we just miss that... Is this not the right target? What do you think? Dr. Brian Bergmark: Yeah, it's a great question. I do think the target itself holds great promise. Obviously, a monoclonal antibody against this same target results in major reductions in apo B, LDL cholesterol, and the latter through a mechanism that is not really known but is not dependent on the LDL receptor, and therefore has real clinical utility that's approved for people with familial homozygous hypercholesterolemia. Beyond that, of course, in genetic studies, there's a clear association with loss of function in the ANGPTL3 gene and lower levels of all of these lipids, lower rates of coronary artery disease, et cetera. Dr. Brian Bergmark: So, I think it's not that this pathway is not promising and actually already being taken advantage of, I think it's that this particular agent acting through this mechanism was not able to achieve a necessary efficacy with reasonable safety. Some genetic data suggests that there is not actually a dose response between a reduction or loss of function in ANGPTL3 and reduction in apo B or lower levels of apo B and non-HDL cholesterol, but it really requires your complete elimination of ANGPTL3 function, which is probably, likely achieved with the monoclonal antibody. And so, even though we had quite large reductions with the antisense oligonucleotide, perhaps, we just didn't cross that threshold that's needed to modify the lipid panel in the way that would've been clinically meaningful. Dr. Parag Joshi: Yeah. I think that's fantastic as you allude to with evolocumab and the impact that has on apo B levels. I didn't think of it as a threshold effect, but that makes a lot of sense as maybe that just getting to that tipping point is where the issue is here. In terms of the liver signal, what were your thoughts on that? And is that something that we should expect to see in ASOs or do you think it's specific to this compound? Dr. Brian Bergmark: Yeah, I don't know. That was unexpected. Right, there are two liver signals and it's unclear how related they are. One is the inflammation of the liver as indicated by the elevation in enzymes, and then the other is the fat accumulation. So with respect to the fact, if anything, genetic data suggests perhaps loss of function in ANGPTL3 might result in lower rates of hepatic steatosis. In animal models, the antisense oligonucleotide reduces liver fat, and so there's, there was promise going into this that this could actually be beneficial for non-alcoholic fatty liver disease. And additionally, there's not data to suggest that the monoclonal antibody increases liver fat. So, there's not a lot to support this as being an on-target effect that by inhibiting ANGPTL3, by that pathway, the liver fat was increased. So, I think a reasonable person might wonder whether this was an off-target effect of the drug. Dr. Brian Bergmark: By what mechanism that occurred, I don't know, what the implications would be for other related agents, I don't know. And then similarly, the liver enzyme elevations, is that related to this? I'm not exactly sure, but also unexpected and I think off-target. But that sort of intrinsic to this mechanism of hepatic targeting, is this something we need to be worried about for other agents in this class or not? I don't know. Obviously, we can't answer that from this single study. We are going to dive into it a bit more to try to overlay patients with hepatic fat accumulation, liver enzymes, et cetera. Of course, both of those happen more at higher doses. How much we can really parse this? I'm not sure yet. Dr. Parag Joshi: Yeah. That's really fascinating. I think the appeal of this paper to the circulation audience is that you have a really exciting novel target and pathway to explore here but somewhat divergent results from what's existing in this space. And I think that raises a lot of questions, really interesting questions going forward for this space. For the ANGPTL3 pathway, what do you see there coming down the line or what are your thoughts on that going forward for this target and ways to approach risk related to it? Dr. Brian Bergmark: Yeah. Great. Thank you. Yeah. No, so I agree. I think moving into this other end of the spectrum of triglyceride-rich lipoproteins, et cetera, I think this is where we're headed and this is why we do the trial. We weren't expecting these things that's why you do this experiment, and this is what we found. So now, where do we go from here? So there are, of course, other ways beyond the monoclonal antibody of targeting ANGPTL3 specifically. There's siRNA, there is gene therapy being investigated. So, I think all of them hold an great promise. And of course, we will need to see as those therapies move along what the actual trials show. And then there are, of course, other pathways that are of interest, APOC3, for instance. So, I think there's a lot more in this space that's coming down the line. Dr. Parag Joshi: Yeah, absolutely. I think it's a really exciting space, and we're really happy to get this paper as one piece of that whole puzzle. So, thank you. Dr. Mercedes Carnethon: Yes. And I echo that as well. And as a methodologist myself, I'm always really pleased to see such well-designed studies. I think this was sophisticated in many aspects in testing different dosing and different timing of the dosing. And also, I'm really impressed by your inclusion criteria, particularly when I noted that 44% of the participants were female, and that you reported those stratum-specific effects. I just had a final question as we wrap up. You acknowledge a nominally significant interaction by sex and I see, for example, that it appears that the magnitude is larger possibly in the relatively smaller subset of females as compared with males. Is this something to pay attention to or do you think this is just some type of an artifact related to greater variability because the group is smaller? Dr. Brian Bergmark: Yeah, it's a good question. So, this is the burning question. We had no a priority reason to suspect that biologically and we are not adjusting for multiple testing in the key value of 0.04. So just to put my money down, I would say, I would guess it's random chance. We found it. It's worthy of looking into a bit more. There were, of course, the important implications for other drugs, et cetera. So, I think it's worth diving into as we will, but are we likely to uncover some biological difference? I doubt it. I wouldn't guess. There are other subgroups where I think at least upfront, you might expect there could be a difference. So, there are thoughts about insulin's effect on LPL. Could diabetes status have an interaction with the drug? I think though not statistically significant, it's also something worth looking into that group and the subfractions of the lipid panel and all of that stuff. So, I think it's all worth looking into but cautiously with the constraints. Dr. Mercedes Carnethon: Well, thank you so much for that explanation. And I've really enjoyed this discussion with you today, Brian, and you, Parag. I've certainly learned a lot and I'm really excited to see this excellent work coming out in the journal circulation. So, thank you very much for your time this morning and thank you to our listeners. Wrapping up this episode of Circulation on the Run. Dr. Greg Hundley: This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

[Werbung] und zwar in eigener Sache: Nicht besetzte Stellen und nicht vorhandene Skills sind zwei der größten Hindernisse bei der der Digitalisierung im Krankenhaus. Verschärft wurde dieser Fachkräftemangel auch durch regulatorische Vorgaben wie das KHZG und die diversen TI-Projekte. Da wir Krankenhaus-IT-Wissen hier im Podcast seit über 6 Jahren behandeln, als Professoren sowieso an unserer Didaktik feilen und pandemiebedingt viele interaktive Lehrkonzepte ausprobiert haben, wollen wir bei diesem Problem des  Fachkräftemangels helfen und haben in Kooperation mit der Digital Avantgarde in den letzten 1,5 Jahren fleißig Lehreinheiten zu den wichtigsten Krankenhaus-IT-Themen erstellt. Begonnen haben wir mit dem Thema "Krankenhaus", das sich wiederum in Krankenhausprozesse (Klinischer Kernprozess, Auftragskommunikation, Pflegeprozess, Medikation, Abrechnung, OP-Management, Termin- und Ressourcenmanagement, Klinische Pfade, Reifegradmodelle ...) und Krankenhaussoftware (KIS, RIS, PACS, PDMS, Archiv ...) unterteilt. Ein weiterer, großer Block ist die "Interoperabilität" mit Kommunikationsstandards (HL7v2, FHIR, CDA, HL7v3 ...), Semantische Interoperabilität (OPS, ICD, LOINC, SNOMED CT, PZN, ATC..), Prozessuale Interoperabilität (IHE, DICOM) und passender Software (Kommunikationsserver). Abgerundet wird das Lehrangebot durch "Regulatorische Bedingungen" wie z.B. Patientenrechte, KHZG, TI usw. sowie Methodik (u.a. Projektmanagement, Anforderungsermittlung und -priorisierung, Agile Methoden). Shownotes: Digital Avantgarde Akademie WebseiteE-Mail an akademie@digital-avantgarde.de Auf der DMEA sind wir auch regelmäßig beim Stand der Digital Avantgarde, Meldet Euch einfach, wenn das Schulungsangebot für Euch interessant sein sollte.

丽莎老师讲机器人之土耳其比尔肯大学巴掌大的新型微型机器人欢迎收听丽莎老师讲机器人，想要孩子参加机器人竞赛、创意编程、创客竞赛的辅导，找丽莎老师！欢迎添加微信号：153 5359 2068，或搜索钉钉群：31532843。近日，土耳其毕尔肯大学的研究人员发明了一款微型四足机器人——SQuad。与现有微型机器人不同的是，SQuad用软材料制成，行动更加灵活，可以攀越其身高2.44倍的障碍，也能绕开障碍物。未来，SQuad或能用于检查狭小空间、在废墟中搜救等。土耳其毕尔肯大学的研究人员研究微型机器人已有将近10年时间，微型机器人有许多优点，比如所需材料较少、成本低廉、能够进入狭窄空间等。但是，现有微型机器人的缺点也比较突出。“他们的主要缺点之一是缺乏运动能力，特别是在不平坦地形上。”微型机器人的高度有限，运动时无法攀爬或避开障碍物，因此很容易在运动过程中被卡住。相比于微型机器人，软体机器人的运动性能更好。大多数软体机器人都是用气动执行器制造的。研究人员介绍：“这些气动执行器可以和软材料实现非常好的集成效果，但是它们需要一个压缩气源，这往往会使机器人变得笨重、或不允许无绳运动。研究团队试图将两种机器人的优点加以结合，制作出综合性能更好的机器人。首先，选用聚二甲基硅氧烷（PDMS）等软材料来增加微型机器人的“身体顺应性（body compliance）”，使其运动能力变强。通过使我们的微型机器人变得柔软，它们能够利用自己的身体顺应性越过障碍，就像昆虫、老鼠等生物系统那样。同时，微型机器人搭载常规执行器来实现小型化和无绳移动。经过尝试，研究人员制成了微型四足机器人SQuad。该机器人有手掌大小，装配了集成直流电动机的柔性C型腿，可以自由旋转。研究人员通过一系列试验评估了SQuad的性能，并将其与一个刚性材料制成的机器人进行比较。结果显示，SQuad的运动性能更好。SQuad能够爬过比其身高还高1.44倍的障碍物，但刚性机器人只能爬过其身高0.88倍的障碍物。研究人员认为，这是因为两款机器人身体顺应性的差异。在未来，SQuad可以在陆地上完成各种简单的任务。由于具备高度灵活性、身体顺应性和增强的穿越障碍能力，SQuad可以爬过狭小的开口及在非结构化或不平坦的地形上运动。研究人也对SQuad的应用表现出信心，“他们认为，通过在机器人背上加一个小型摄像机，我们可以将这种机器人用于检查目的；通过集成一个摄像机和麦克风，就可以将其用于在倒塌的建筑物下寻找幸存者。”结语：设计还在更新，或增加身体收缩机制土耳其毕尔肯大学研究人员推出的微型四足机器人集合了传统微型、软体机器人的优点，能够爬越身高2.44倍高的障碍物，未来或可应用于检查、救援等场景。此外，为了使SQuad能够应用于更多场景，研究人员还在继续更新设计，钻研能提升机器人步态和动作的技术及性能更好的新型聚合物。研究团队正在增加一个身体收缩机制，“（它能）使我们的机器人在通过比其横截面面积小的开口时，短暂地收缩身体，就像老鼠的行为那样。我们还在研究机器人的动力学模型，以便更好地理解微型机器人、软体机器人的运动。”

丽莎老师讲机器人之土耳其比尔肯大学巴掌大的新型微型机器人欢迎收听丽莎老师讲机器人，想要孩子参加机器人竞赛、创意编程、创客竞赛的辅导，找丽莎老师！欢迎添加微信号：153 5359 2068，或搜索钉钉群：31532843。近日，土耳其毕尔肯大学的研究人员发明了一款微型四足机器人——SQuad。与现有微型机器人不同的是，SQuad用软材料制成，行动更加灵活，可以攀越其身高2.44倍的障碍，也能绕开障碍物。未来，SQuad或能用于检查狭小空间、在废墟中搜救等。土耳其毕尔肯大学的研究人员研究微型机器人已有将近10年时间，微型机器人有许多优点，比如所需材料较少、成本低廉、能够进入狭窄空间等。但是，现有微型机器人的缺点也比较突出。“他们的主要缺点之一是缺乏运动能力，特别是在不平坦地形上。”微型机器人的高度有限，运动时无法攀爬或避开障碍物，因此很容易在运动过程中被卡住。相比于微型机器人，软体机器人的运动性能更好。大多数软体机器人都是用气动执行器制造的。研究人员介绍：“这些气动执行器可以和软材料实现非常好的集成效果，但是它们需要一个压缩气源，这往往会使机器人变得笨重、或不允许无绳运动。研究团队试图将两种机器人的优点加以结合，制作出综合性能更好的机器人。首先，选用聚二甲基硅氧烷（PDMS）等软材料来增加微型机器人的“身体顺应性（body compliance）”，使其运动能力变强。通过使我们的微型机器人变得柔软，它们能够利用自己的身体顺应性越过障碍，就像昆虫、老鼠等生物系统那样。同时，微型机器人搭载常规执行器来实现小型化和无绳移动。经过尝试，研究人员制成了微型四足机器人SQuad。该机器人有手掌大小，装配了集成直流电动机的柔性C型腿，可以自由旋转。研究人员通过一系列试验评估了SQuad的性能，并将其与一个刚性材料制成的机器人进行比较。结果显示，SQuad的运动性能更好。SQuad能够爬过比其身高还高1.44倍的障碍物，但刚性机器人只能爬过其身高0.88倍的障碍物。研究人员认为，这是因为两款机器人身体顺应性的差异。在未来，SQuad可以在陆地上完成各种简单的任务。由于具备高度灵活性、身体顺应性和增强的穿越障碍能力，SQuad可以爬过狭小的开口及在非结构化或不平坦的地形上运动。研究人也对SQuad的应用表现出信心，“他们认为，通过在机器人背上加一个小型摄像机，我们可以将这种机器人用于检查目的；通过集成一个摄像机和麦克风，就可以将其用于在倒塌的建筑物下寻找幸存者。”结语：设计还在更新，或增加身体收缩机制土耳其毕尔肯大学研究人员推出的微型四足机器人集合了传统微型、软体机器人的优点，能够爬越身高2.44倍高的障碍物，未来或可应用于检查、救援等场景。此外，为了使SQuad能够应用于更多场景，研究人员还在继续更新设计，钻研能提升机器人步态和动作的技术及性能更好的新型聚合物。研究团队正在增加一个身体收缩机制，“（它能）使我们的机器人在通过比其横截面面积小的开口时，短暂地收缩身体，就像老鼠的行为那样。我们还在研究机器人的动力学模型，以便更好地理解微型机器人、软体机器人的运动。”

Establishing Trust & Accountability Within A Remote WorkforceThis week, we are launching Toptal’s “Rise of Remote” series, a special edition of The Talent Economy Podcast, featuring advice and perspectives from experts in remote work. Prompted by the COVID-19 pandemic that has accelerated the gradual advance of remote work into a stampede, we thought it was extraordinarily relevant to create a special series dedicated to hearing from experts on how to succeed when working remotely. In this episode, I’m joined by Toptal’s VP of Product, Kleanthis Georgaris.Kleanthis drives the evolution of Toptal's platform and associated products, working closely with operations and engineering teams to drive and support our hypergrowth by providing a seamless, on-demand experience for clients and network talent. He specializes in digital talent networks, leveraging a diverse background at Microsoft, McKinsey, and many early- and late-stage startups, as well as launching a startup of his own.Kleanthis and I discuss remote work best practices and how to structure a product team in, and for, a remote environment. We deep dive into the importance of communication, transparency, work-life balance, and how to overcome the “trust barriers” that often stereotype remote work.Questions I ask:What has been your journey from working on location to now managing and leading a team in a fully remote, distributed environment?What advice would you give to other leaders, or first-time remote PdMs, on the frequency of team communication to ensure transparency?What are Toptal’s best practices for a product brainstorming or ideation exercise?How would you describe the impact of the current global crisis on remote work?In this episode, you will learn:Kleanthis’ advice to product leaders on staying connected in a remote environment.What sets Toptal apart.How to manage information overload in a remote setting by identifying information from noise.Kleanthis’ advice to managers and employees on how to be successful and stay connected when working remotely.Connect with Kleanthis:LinkedInEmail: kleanthis@toptal.com See acast.com/privacy for privacy and opt-out information.

In Folge 85 geht es mal wieder um Informationssysteme im Krankenhaus und wir schauen auf die Intensivstation. Dort sind Patientendatenmanagementsysteme (PDMS) unverzichtbare Helfer für das Monitoren von Vitaldaten. Welche Aufgabe diese Systeme darüber hinaus übernehmen, ob dafür eine Zertifizierung als Medizinprodukt notwendig ist und wie es sich so mit der Interoperabilität dieser Systeme verhält erläutert Bernhard zusammen mit seinem Gast Janko Ahlbrandt. In den News zuvor sprechen Christian und Renato über die Nutzenbewertung von Apps und synthetische Daten, ehe sie Richtung Metall-spielender KI abdriften. Und ein Intro gibt es diesmal auch wieder :-) Shownotes https://www.xing.com/profile/Janko_Ahlbrandt/cv https://www.aerztezeitung.de/politik_gesellschaft/psychotherapeutische_versorgung/article/993154/psychotherapeuten-mahnen-medizinische-apps-brauchen-nutzennachweis.html?sh=2&h=541880579 https://www.nature.com/articles/s41467-019-10933-3

欢迎收听丽莎老师讲机器人，想要孩子参加机器人竞赛、创意编程、创客竞赛的辅导，找丽莎老师！欢迎添加微信号：153 5359 2068，或搜索微信公众号：我最爱机器人。丽莎老师讲机器人之人造毛毛虫？多腿机器人。香港城市大学(CityU)的研究人员开发出了一种新型的微型软机器人。它的腿像毛毛虫一样，可以承受较大负载并能适应恶劣的环境。这种微型运输机器人可以为人体内药物运输技术铺平道路。让这个微型机器人脱颖而出的是它数百条不到1毫米的尖腿。而这种独特的设计并不是随意为之，研究小组研究了数百种地面动物的腿部结构，特别是腿长和腿间距的比例，研究对象包括那些有2条、4条、8条或更多腿的动物，从那里，他们得到了灵感。机器人的身体厚度约为0.15毫米，每条锥形腿长0.65毫米，两腿之间的距离约为0.6毫米，腿长与腿宽之比约为1:1。锥形的腿大大减少了机器人与物体表面的接触面积，从而减少了与表面的摩擦。实验室测试表明，这种多腿机器人在干、湿环境下的摩擦力比无腿机器人小40倍。除了多腿设计，材料也很重要。该机器人由嵌入了磁性颗粒的聚二甲基硅氧烷(PDMS)制成，因此通过施加电磁力就能远程控制机器人。通过磁力控制，机器人可以以襟翼推进模式或倒立摆模式移动，也就是说，它可以用前脚向前翻腾，也可以用左右脚交替站立来摆动身体。香港城市大学机械工程系(MNE)的教授说：“人体内不同组织的崎岖表面和变化的纹理使体内运输极具挑战性。我们的多腿机器人在各种地形中都表现出了令人印象深刻的性能，因此在身体内药物输送方面具有广阔的应用前景。”研究小组进一步证实，当机器人遇到比他的腿长十倍的障碍物时，机器人能够抬起身体的一端，形成90度的角度，然后很容易地穿过障碍物。该机器人还可以通过增加电磁频率来提高移动速度。此外，该机器人还显示了出色的负载能力。实验室测试表明，该机器人能够承载比自己重100倍的负载。这种机器人具有超强的携带能力、高效的移动能力和良好的穿越障碍的能力，因此非常适合在恶劣的环境下使用，例如穿越消化系统将药物送到指定地点。但是，在对动物和人类进行进一步的测试之前，研究团队正在从三个方面进一步发展和完善他们的研究，即找寻一种可降解的材料，研究新的机器人形状，并添加额外的功能。研究团队说希望在未来两到三年内制造出一种可生物降解的机器人，这样它就能在完成药物运送任务后自然分解。

KIS, RIS, PACS, DMS, PDMS, LIS.. Was wäre die Krankenhaus-IT nur ohne Abkürzungen? Und was wäre sie ohne einen Kommunikationsserver zwischen diesen ganzen Abkürzungen, der Sprachbarrieren überwindet und Kommunikation sicherstellt? In Podcast #43 erläutern Renato und Christian, warum in vielen Krankenhäusern heutzutage Kommunikationsserver stehen, was diese so alles können müssen, welche Vor- und Nachteile sich aus ihrem Einsatz ergeben und welche Anbieter es gibt. Als News gibt es in diesem Podcast den ersten Arzt, der an der Telematikinfrastruktur angeschlossen wurde, eine smarte Pille, die dem Arzt meldet, wenn sie im Magen angekommen ist, den Börsengang der Healthineers und ein Statement der Ethikkommission zum Thema Big-Data in der Medizin.   http://www.healthcaremarketing.eu/unternehmen/detail.php?rubric=Unternehmen&nr=52523&nr=52523#52523 http://www.ethikrat.org/presse/pressemitteilungen/2017/pressemitteilung-08-2017 http://e-health-com.de/details-unternehmensnews/cgm-bindet-erste-praxis-an-die-telematikinfrastruktur-an/3360afa121ed5e2575e2b51ca5b76a6f/ http://podplayer.net/#/?id=43496939 https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584933.htm

This video is a tutorial on performing O2 plasma treatment of PDMS using a microwave oven. The demonstration includes how to set up the treatment, as well as testing the hydrophobicity of the treated PDMS.

This video is a tutorial of how to prepare nickel-doped PDMS. A series of tests of the thermal, electrical, and magnetic properties of different concentrations of doping are shown.

This video is a demonstration of three tests on microfluidic devices on the MIT logo and a fluid flow visualization.

This video is a tutorial of preparing a test pattern through a process of curing the PDMS, opening the microfluidic inlet and outlet ports, cleaning the PDMS, bonding it to glass, and using corona treatment.

Oxygenic photosynthesis converts light energy into chemical energy and is responsible for generating most of our atmosphere’s oxygen and biomass on earth. Several multimeric protein complexes are involved in the underlying photosynthetic electron transfer chain with photosystem II (PSII) representing the initial complex mediating the extraction of electrons from water molecules, thus generating molecular oxygen as a by-product. During recent years, the structural details and components of the PSII complex, including its inorganic and organic cofactors, have been elucidated in great detail. However, little is known about the assembly pathway of this at least 20 protein subunits containing machinery. Previous work indicated that PSII assembly occurs in a step-wise fashion and requires a number of facilitating factors, which interact transiently with nascent PSII complexes. Earlier studies of one of those assembly factors, the cyanobacterial PratA protein, suggested that PSII biogenesis does not only underlie a temporal order but is also organized at the spatial level, as PratA was shown to mark a special intermediate membrane subfraction (PDMs), hypothesized to represent regions for initial steps of PSII biogenesis. The presented work focused on a more detailed characterization of PDMs, clearly supporting their significance not only with regard to early protein assembly, but also concerning pigment synthesis and integration into the PSII precomplexes. The PDMs could further be allocated to special membrane regions, named biogenesis centers, at sites where thylakoid membranes converge to the plasma membrane, thus demonstrating the spatial organization of PSII assembly at the cellular level. Moreover, a novel function of PratA in preloading of PSII with Mn2+ ions, necessary for construction of the water-splitting complex, was discovered. Concomitantly with progression of the assembly, the nascent PSII complexes are transported from the PDMs to the thylakoid membrane system, where Sll0933 – a novel PSII assembly factor identified in this thesis – mediates the integration of the PSII inner antenna proteins followed by completion of the assembly process. Additionally, it could be shown that many of the so far identified facilitating factors interact with each other and, thus, form a complex network for PSII assembly. Especially the interaction between the two assembly factors YCF48 and Sll0933 was characterized in more detail, revealing a successive mode of action with YCF48 operating upstream of Sll0933. Taken together, the presented results enable the development of an extended and elaborated model of PSII assembly, which is a concerted process connecting protein and cofactor synthesis/integration in a spatiotemporal manner, and thus contribute to a more profound understanding of photosynthesis itself.

The article by Rajendrani Mukhopadhyay explores the pros and cons of PDMS as a material for microfluidic devices.